Announcing Fungible Storage Cluster with Support for VMware vSphere
7.6.2022 16:01:00 EEST | Business Wire | Press release
Fungible Inc., the dynamic composable infrastructure company, today announced a new release of Fungible Storage Cluster® (FSC) 4.1, providing support for VMware vSphere® environments requiring high-performance.
Virtual machines provide unparalleled flexibility in managing complex and changing compute environments. Workloads running in virtualized environments can have varied storage requirements. For demanding workloads, Fungible’s high-performance all-flash array based on NVMe/TCP is now certified for vSphere and available for VMware virtualized environments. The latest release (4.1) will now enable customers to experience the superior manageability of vSphere combined with the high performance of Fungible’s Storage Cluster.
"NVMe/TCP enables vSphere customers to accelerate their storage performance while leveraging existing investments and lowering complexity,” said Marc Fleischmann, Cloud CTO, VMware, “Through collaboration with innovative companies such as Fungible, VMware continues to build a world-class ecosystem of technology partners that offer our customers flexibility and choice to meet their business requirements.”
Customers can plug FSC storage into their ESXi servers with NVMe/TCP and get what appears to be local storage. The resulting performance is nearly identical to local storage even though it is a shared resource providing economic benefits to match the performance benefits.
“VMware vSphere is the virtualization infrastructure of choice for a variety of mission-critical, performance-sensitive workloads in the data center,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies at IDC. “As IT organizations deploy more workloads that require accelerated compute and storage, the use of composable, disaggregated infrastructure (CDI) like that available from Fungible will be deployed more often to enable the more efficient use of these types of resources in VMware environments. IDC expects that the CDI market overall will top $4.8 billion by 2025.”
“VMware has long led the drive to improve flexibility and utilization of data center infrastructure. Now with the latest release of our vSphere certified Fungible Storage Cluster, VMware users can further enhance their ability to tune demanding workloads to get the utmost performance and flexibility,” said Pradeep Sindhu, Co-Founder and CDO of Fungible. “Trade-offs of flexibility versus performance are no longer required. Pairing VMware with NVMe/TCP for storage access with our DPU-powered Storage Cluster allows VMware customers to address the performance requirements of today's modern applications.”
With FSC, vSphere users may also see storage cost savings since FSC’s erasure coding provides robust data protection which can be less expensive than traditional RF1 or RF2 replication. Additionally, Fungible’s composable data infrastructure provides flexibility to compose storage to meet current needs and recompose it to adapt to changing needs providing outstanding investment protection.
To learn more about the new FSC 4.1 and the VMware vSphere certification and how you can get more value and performance from your VMware vSphere resources click here or contact sales@fungible.com.
About Fungible:
Silicon Valley-based Fungible, the world’s premier dynamic composable infrastructure company, creates solutions to cloudify the world’s data centers by utilizing the Fungible DPU™ to connect CPUs, GPUs, and storage via NVMe/TCP over standard IP/Ethernet networks. Fungible aims to revolutionize the performance, economics, reliability and security of scale-out data centers. Visit Fungible to learn more. Follow us on Twitter and LinkedIn.
Fungible and Fungible FSC are registered trademarks of Fungible, Inc. VMware and vSphere are registered trademarks or trademarks of VMware, Inc. in the United States, and other jurisdictions. This article may contain hyperlinks to non-VMware websites that are created and maintained by third parties who are solely responsible for the content on such websites.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005155/en/
Contact information
Jennifer Bell
Fungible, Inc.
(669) 292-5522
press@fungible.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom